Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 28,982 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Neurological Disorder Clear all
Active, not recruiting Phase 2 Interventional

Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation

NCT07354477
View directory record Official record
Conditions
Non-proliferative Diabetic Retinopathy (NPDR), Open-angle Glaucoma (OAG), Normal Tension Glaucoma (NTG)
Interventions
QLS-111 Ophthalmic Solution (0.015%), QLS-111 Ophthalmic Solution (0.075%)
Drug
Lead sponsor
Qlaris Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 21, 2026, 5:38 AM EDT
Completed Not applicable Interventional Results available

XIENCE 28 USA Study

NCT03815175
View directory record Official record
Conditions
Bleeding Disorder, Ischemic Stroke, Hemorrhagic Stroke, Hematological Diseases, Thrombocytopenia, Coagulation Disorder, Anemia, Renal Insufficiency, Coronary Artery Disease
Interventions
XIENCE, DAPT (aspirin and/or P2Y12 receptor inhibitor)
Device · Drug
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years to 100 Years
Enrollment
1,605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
54
States / cities
Huntsville, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated May 3, 2022 · Synced Oct 21, 2026, 5:38 AM EDT
Completed Phase 3 Interventional Results available

A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain

NCT03213457
View directory record Official record
Conditions
Endometriosis
Interventions
Estradiol/Norethindrone Acetate, Placebo for Elagolix, Elagolix, Placebo for E2/NETA
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
681 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
188
States / cities
Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 140 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2024 · Synced Oct 21, 2026, 5:38 AM EDT
Completed Not applicable Interventional

Effects of Droxidopa When Measuring Gait Speed, Kyphosis, and Functional Reach in Parkinson's Disease

NCT03173781
View directory record Official record
Conditions
Parkinson's Disease
Interventions
droxidopa, Placebo
Drug
Lead sponsor
Colorado Springs Neurological Associates
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Colorado Springs, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 25, 2018 · Synced Oct 21, 2026, 5:38 AM EDT
Completed Phase 2 Interventional

APX005M and Doxorubicin in Advanced Sarcoma

NCT03719430
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
Doxorubicin, APX005M
Drug
Lead sponsor
Alexander Z. Wei, MD
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
3
States / cities
Duarte, California • St Louis, Missouri • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 21, 2026, 5:38 AM EDT
Completed Phase 2Phase 3 Interventional

Efficacy and Safety of Intravenous Neridronic Acid in CRPS-I

NCT02402530
View directory record Official record
Conditions
Complex Regional Pain Syndrome, Type I
Interventions
Placebo, Neridronic acid 62.5 mg
Drug
Lead sponsor
Grünenthal GmbH
Industry
Eligibility
18 Years to 80 Years
Enrollment
459 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
49
States / cities
Foley, Alabama • Scottsdale, Arizona • Tucson, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated May 9, 2018 · Synced Oct 21, 2026, 5:38 AM EDT
Completed Not applicable Interventional Results available

Iowa Cochlear Implant Clinical Research Center Hybrid L24 and Standard Cochlear Implants in Profoundly Deaf Infants

NCT03156465
View directory record Official record
Conditions
Implants, Cochlear, Child, Hearing Loss, Bilateral
Interventions
Hybrid L24
Device
Lead sponsor
University of Iowa
Other
Eligibility
12 Months to 24 Months
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
2
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Oct 21, 2026, 5:38 AM EDT
Completed Phase 1 Interventional Results available

Topotecan by Intracerebral Clysis for Recurrent Primary Malignant Brain Tumors

NCT00308165
View directory record Official record
Conditions
Brain Neoplasms, Primary Malignant
Interventions
Convection-Enhanced Delivery, Topotecan
Procedure · Drug
Lead sponsor
Columbia University
Other
Eligibility
1 Year and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 21, 2026, 5:38 AM EDT
Not yet recruiting Phase 2 Interventional

Evaluation of Echothiophate in Pediatric Patients With Refractory Amblyopia

NCT07554131
View directory record Official record
Conditions
Refractory Amblyopia
Interventions
Echothiophate Iodide 0.125% Ophthalmic Solution
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
3 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 21, 2026, 5:38 AM EDT
Completed Phase 3 Interventional Results available

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer

NCT00820222
View directory record Official record
Conditions
Metastases, Brain
Interventions
capecitabine, lapatinib, trastuzumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
17
States / cities
Goodyear, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2019 · Synced Oct 21, 2026, 5:38 AM EDT
Active, not recruiting Not applicable Interventional

A Randomized Control Trial of Motor-based Intervention for CAS

NCT04642053
View directory record Official record
Conditions
Childhood Apraxia of Speech
Interventions
Dynamic Temporal and Tactile Cuing
Behavioral
Lead sponsor
New York University
Other
Eligibility
29 Months to 95 Months
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 21, 2026, 5:38 AM EDT
Completed Not applicable Interventional

Prospective Evaluation of Reduced Impedance Noninvasive Cortical Electrostimulation (RINCE) to Reduce Fibromyalgia Effects - Extension Study

NCT01958853
View directory record Official record
Conditions
Fibromyalgia
Interventions
RINCE
Device
Lead sponsor
Cerephex Corporation
Industry
Eligibility
22 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Pontiac, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 17, 2015 · Synced Oct 21, 2026, 5:38 AM EDT
Completed Phase 3 Interventional Results available

An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride HCl) Oral Solution in Children and Young Adults With Dravet Syndrome

NCT02823145
View directory record Official record
Conditions
Dravet Syndrome
Interventions
ZX008 (Fenfluramine Hydrochloride)
Drug
Lead sponsor
Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
Industry
Eligibility
2 Years to 35 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
24
States / cities
Phoenix, Arizona • Tucson, Arizona • Orange, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Oct 21, 2026, 5:38 AM EDT
Active, not recruiting Not applicable Interventional

rTMS Plus CCFES-mediated Functional Task Practice for Severe Stroke

NCT03870672
View directory record Official record
Conditions
Stroke, Hemiplegia, Cerebrovascular Accident (CVA), Hemiparesis
Interventions
Contralaterally Controlled Functional Electrical Stimulation, New rTMS approach, Conventional rTMS approach, Sham rTMS approach
Device
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 21, 2026, 5:38 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Assessing Comorbidities in Epilepsy Using Eye Movement Recordings

NCT06310772
View directory record Official record
Conditions
Childhood Absence Epilepsy, Absence Seizures, Epilepsy Comorbidities
Interventions
Not listed
Lead sponsor
Eysz, Inc.
Industry
Eligibility
4 Years to 12 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Orange, California • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 21, 2026, 5:38 AM EDT
Not listed Phase 4 Interventional

Mecamylamine for Autonomic Dysreflexia Prophylaxis

NCT03914677
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Mecamylamine Oral Tablet
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Oct 21, 2026, 5:38 AM EDT
Completed Phase 2 Interventional Results available

Trial of Dronabinol Adjunctive Treatment of Agitation in Alzheimer's Disease

NCT02792257
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Dronabinol (Marinol®), Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
60 Years to 95 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
5
States / cities
Miami, Florida • Baltimore, Maryland • Belmont, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated May 9, 2025 · Synced Oct 21, 2026, 5:38 AM EDT
Completed Phase 1 Interventional

Sleep Enhancement Training Study for Experienced Shiftworkers

NCT00786357
View directory record Official record
Conditions
Shift-Work Sleep Disorder
Interventions
NIOSH shiftwork booklet, Sleep Enhancement Training System
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2010 · Synced Oct 21, 2026, 5:38 AM EDT
Completed No phase listed Observational

Non-drug Study to Evaluate the Suitability of Neurocognitive Tests and Functioning Scales for the Measurement of Cognitive and Functioning Changes in Children With Down Syndrome

NCT02451657
View directory record Official record
Conditions
Down Syndrome
Interventions
No Intervention
Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
6 Years to 11 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Tucson, Arizona • Boston, Massachusetts • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 25, 2017 · Synced Oct 21, 2026, 5:38 AM EDT
Withdrawn Not applicable Interventional

Mag Con: Efficacy of Oral Mag. in Acute Concussion in Adolescents

NCT05065528
View directory record Official record
Conditions
Concussion, Mild, Traumatic Brain Injury, Mild
Interventions
Magnesium, Placebo
Dietary Supplement · Drug
Lead sponsor
Corewell Health South
Other
Eligibility
12 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Saint Joseph, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 29, 2024 · Synced Oct 21, 2026, 5:38 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery

NCT02180867
View directory record Official record
Conditions
Alveolar Soft Part Sarcoma, Angiomatoid Fibrous Histiocytoma, Atypical Fibroxanthoma, Clear Cell Sarcoma of Soft Tissue, Epithelioid Malignant Peripheral Nerve Sheath Tumor, Epithelioid Sarcoma, Extraskeletal Myxoid Chondrosarcoma, Extraskeletal Osteosarcoma, Fibrohistiocytic Neoplasm, Fibrosarcoma, Inflammatory Myofibroblastic Tumor, Intimal Sarcoma, Leiomyosarcoma, Liposarcoma, Liver Embryonal Sarcoma, Low Grade Fibromyxoid Sarcoma, Low Grade Myofibroblastic Sarcoma, Malignant Peripheral Nerve Sheath Tumor, Malignant Skin Granular Cell Tumor, Malignant Triton Tumor, Mesenchymal Chondrosarcoma, Myxofibrosarcoma, Myxoid Chondrosarcoma, Myxoinflammatory Fibroblastic Sarcoma, Nerve Sheath Neoplasm, PEComa, Pericytic Neoplasm, Plexiform Fibrohistiocytic Tumor, Sclerosing Epithelioid Fibrosarcoma, Skin Glomus Tumor, Stage IB Soft Tissue Sarcoma AJCC v7, Stage IIB Soft Tissue Sarcoma AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Synovial Sarcoma, Undifferentiated High Grade Pleomorphic Sarcoma of Bone
Interventions
Doxorubicin, Doxorubicin Hydrochloride, Ifosfamide, Pazopanib, Pazopanib Hydrochloride, Radiation Therapy, Therapeutic Conventional Surgery
Drug · Radiation · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
365
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 240 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 21, 2026, 5:38 AM EDT
Active, not recruiting No phase listed Observational

A Prospective Natural History and Outcome Measure Discovery Study of Charcot-Marie-Tooth Disease, Type 4J

NCT06151600
View directory record Official record
Conditions
Peripheral Neuropathy, Neuro-Degenerative Disease, Neuromuscular Diseases
Interventions
Not listed
Lead sponsor
Elpida Therapeutics SPC
Industry
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
3
States / cities
San Francisco, California • Iowa City, Iowa • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 21, 2026, 5:38 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Sex Steroids, Sleep, and Metabolic Dysfunction in Women

NCT00805207
View directory record Official record
Conditions
Polycystic Ovary Syndrome (PCOS), Obstructive Sleep Apnea, Obesity
Interventions
Progesterone, testosterone, glucocorticoid, continuous positive airway pressure, Estrogen, Control
Drug · Device · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Oct 21, 2026, 5:38 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Youth Soccer Header Study

NCT04919707
View directory record Official record
Conditions
Brain Injuries
Interventions
Header Session, MRI Session
Behavioral · Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
12 Years to 18 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 4, 2022 · Synced Oct 21, 2026, 5:38 AM EDT